Targets › ALMS1
1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout May 2027.
Involved in PCM1-dependent intracellular transport. Required, directly or indirectly, for the localization of NCAPD2 to the proximal ends of centrioles. (UniProt, Q8TCU4)
Open in Phaseline: the race on ALMS1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AdipoPharma | PATAS Trifluoroacetate Modulator of ALMS1-PKC alpha interaction | ALMS1, PRKCA | Phase 1 | Type 2 Diabetes | May 2027 |
Type 2 Diabetes (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.